Panel Activity

Case Update – Rolfingsmeyer v. Office of Personnel Management

One of the three cases scheduled to be argued last week at the Federal Circuit that attracted amicus briefs was a death benefit case entitled Rolfingsmeyer v. Office of Personnel Management. Normally at this point we would provide a recap of the oral argument, but last week the Federal Circuit released a nonprecedential order “remov[ing] this case from the March 5, 2021 oral argument calendar and [holding] the case in abeyance for 60 days.” Here is the full text of the court’s order.

Read More
News

Recent News on the Federal Circuit

Here’s the latest.

Read More
Opinions / Panel Activity

Opinion Summary – Euzebio v. McDonough

This week, the Federal Circuit issued its opinion in Euzebio v. McDonough, a veterans case we have been following because it attracted two amicus briefs. Judge Wallach authored a unanimous panel opinion reversing and remanding a decision by the Court of Appeals for Veterans Claims that certain materials were not constructively before the Board of Veterans’ Appeals. This is our opinion summary.

Read More
Opinions

Opinions & Orders – March 5, 2021

This morning, the Federal Circuit issued a nonprecedential opinion in a veterans case and a nonprecedential order denying a petition for an interlocutory appeal. The court also issued two Rule 36 judgments. Here is the introduction to the opinion, text from the order, and links to the Rule 36 judgments.

Read More
Argument Recap / Panel Activity

Argument Recap – GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.

As we previously reported, the Federal Circuit recently conducted a panel rehearing in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. In this case, Teva petitioned the en banc court to reconsider the panel’s decision that Teva induced infringement through use of a skinny label on its generic version of GlaxoSmithKline’s (GSK) drug Coreg. Teva pointed to Hatch-Waxman and asserted that Congress provided a statutory “carve-out” mechanism allowing a generic to adopt a skinny label for unpatented uses that cannot be blocked by a patent on one method of using the drug. The panel treated the motion as requesting panel rehearing and granted panel rehearing. This is our recap of the rehearing oral argument.

Read More
Opinions

Opinions & Orders – March 4, 2021

This morning, the Federal Circuit issued two precedential opinions in government contract cases, one nonprecedential opinion in a veterans case, and one nonprecedential opinion in a patent case. Additionally, the court issued two Rule 36 judgments. Here are the introductions to the opinions and links to the Rule 36 judgements.

Read More
News

Recent News on the Federal Circuit

Here’s the latest.

Read More
Argument Recap / Featured / Supreme Court Activity

Argument Recap – United States v. Arthrex, Inc.

On Monday, March 1, 2021, the Supreme Court heard oral arguments in the closely-watched patent case, United States v. Arthrex. As we previewed a couple days prior to argument, two main issues were considered by the Court. First, for purposes of the Appointments Clause, whether administrative patent judges (APJs) of the Patent Trial and Appeal Board (PTAB) are principal or inferior officers. And second, if APJs are indeed principal officers, whether the Federal Circuit properly cured any Appointments Clause defect through the remedy it provided. Here are the details.

Read More
Opinions

Opinions & Orders – March 3, 2021

This morning, the Federal Circuit issued a precedential opinion in a veterans case and a Rule 36 judgment. Here is the introduction to the opinion and a link to the Rule 36 judgment.

Read More
En Banc Activity

Recent En Banc Activity

Here is an update on recent en banc activity at the Federal Circuit. New petitions were filed in two patent cases raising questions related to claim construction and the doctrine of equivalents. The court also denied seven petitions in patent cases raising questions related to Rule 36 judgments, injunctive relief, claim construction, awards of attorneys’ fees, eligible subject matter, deference to the Patent Trial and Appeal Board, standing, inter partes review, and enablement. Here are the details.

Read More